WASHINGTON D.C. – Key United States health agencies are undergoing sweeping job cuts and significant budgetary reductions under the Trump administration, impacting vital public health functions and regulatory oversight across the nation. Approximately 10,000 workers across entities including the Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), and Centers for Disease Control and Prevention (CDC) are affected by the personnel reductions, according to reports emerging on April 4, 2025.
These drastic measures have reportedly led to the closure of entire offices within these critical agencies, highlighting the depth of the administrative restructuring. One confirmed instance includes the disbandment of the Office of Management at the FDA.
Scale of the Personnel Reductions
The estimated total of 10,000 job cuts represents a substantial portion of the workforce at these federal health organizations. The impacted agencies – the CMS, FDA, and CDC – play pivotal roles in managing healthcare programs, ensuring the safety of food, drugs, and medical devices, and protecting public health through disease prevention and control.
Sources indicate that the reductions are widespread, affecting various levels and divisions within these complex agencies. The closure of specific offices, such as the FDA’s Office of Management, suggests a fundamental alteration of internal operations and administrative capacity.
Budgetary Mandates and Contract Reductions
Parallel to the personnel cuts, the Department of Health and Human Services (HHS), which oversees these agencies, has been directed to implement a significant reduction in spending. A mandate requires HHS to decrease expenditures on contracts by 35% across all its divisions.
This directive was confirmed by HHS spokesperson Andrew Nixon in comments made to NPR. The substantial cut to contract spending is expected to further impact the agencies’ ability to carry out their missions, potentially affecting research, outsourced services, and collaborative projects essential for public health initiatives and regulatory processes.
Impact on the Food and Drug Administration (FDA)
Media reports, prominently including coverage by the Wall Street Journal, have detailed the specific impact on the FDA. The agency responsible for safeguarding the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation, is reportedly reducing its staff by 3,500 individuals.
The cuts within the FDA are affecting various areas, including regulators within the Center for Devices and Radiological Health (CDRH), which is responsible for overseeing medical devices and radiation-emitting products. Amidst these widespread departures, Michelle Tarver has been noted as one of the few senior leaders reportedly remaining within the impacted divisions.
The reductions at the FDA coincide with a noticeable decrease in the pace of device clearances. In the same period of 2025, only 3 novel devices received clearance compared to 13 during the corresponding timeframe in 2024. Similarly, only 4 original devices received premarket approval (PMA) in 2025, a decline from the 8 approved in the prior year. These statistics raise questions about the potential impact of staffing reductions on the agency’s ability to review and approve new medical technologies.
Acknowledgment of Errors and Partial Reversals
Following the initial wave of firings, HHS Secretary Robert F Kennedy Jr. acknowledged that a portion of the job cuts had been made in error. The Secretary stated that approximately 20% of the roughly 10,000 terminations were incorrect.
In light of these acknowledged mistakes, the administration is reportedly taking steps to rectify the situation. Some of the approximately 10,000 terminated employees are being asked to return to their positions. Secretary Kennedy Jr. cited the disbandment of the CDC’s lead poisoning and prevention team as a specific example of an error that occurred during the reduction process.
Broader Implications
The scale of the job cuts and budgetary constraints across CMS, FDA, and CDC is expected to have significant repercussions for the delivery of healthcare services, the pace of medical innovation review, and the nation’s ability to respond to public health threats. While the administration has acknowledged some errors and indicated a willingness to reverse specific firings, the overall reduction in workforce and budget allocation represents a substantial shift in the operational capacity of these critical federal health institutions.
